MPD: Phenotype measures mapped to VT:1000783, immune system trait

Phenotype measures associated with ontology term
VT:1000783 'immune system trait'

All measures in this list are mapped to the ontology descendants of VT:1000783. None are mapped to VT:1000783 directly.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year

Ankra-Badu1:10	Ankra-Badu1	organ weights	(none)	spleen weight [mg] SPLEEN 21210	QTL population		both	10wks	N=502	2009

Auwerx1:195	Auwerx1	cell signaling molecule detection	high-fat diet	blood interferon gamma (INF gamma) amount [pg/mL] inf_gamma 111374 CD HFD	BXD w/par	33	m	29wks	N=4	2016

Auwerx2:135	Auwerx2	organ weights	(none)	spleen weight [g] spleen_wt 114663 CD HFD	inbred w/CC8	9	both	21wks	N=4	2021

Benavides1:1	Benavides1	genotype assessment	(none)	Gpr84 allele deletion in exon 2 (0=yes, 1=no) [designation] Gpr84 48201	inbred w/CC8	58	both	6wks		2013

Benoist1:1	Benoist1	immune cell quantification	(none)	percentage of thymic CD4 Treg cells that are CD25^hi [%] Treg_thy_CD25 25801	inbred	33	m	5-6wks	N=3	2007

Benoist1:2	Benoist1	immune cell quantification	(none)	percentage of thymic CD4 Treg cells that are Foxp3+ [%] Treg_thy_Foxp3 25802	inbred	10	m	5-6wks	N=3	2007

Benoist1:3	Benoist1	immune cell quantification	(none)	percentage of splenic CD4 Treg cells that are CD25^hi [%] Treg_spl_CD25 25803	inbred	31	m	5-6wks	N=3	2007

Benoist1:4	Benoist1	immune cell quantification	(none)	percentage of splenic CD4 Treg cells that are Foxp3+ [%] Treg_spl_Foxp3 25804	inbred	10	m	5-6wks	N=3	2007

Boon1:11	Boon1	body weight	influenza A (H5N1) virus	change in body weight, post-infection [%] bw_change 46911 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:21	Boon1	health assessment	influenza A (H5N1) virus	survival (days to death, max 30) [d] survival 46921 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Boon1:31	Boon1	health assessment	influenza A (H5N1) virus	susceptibility to viral infection (0=susceptible, 1=resistant) [designation] resistance 46931 dosage group: low medium high	inbred	23	f	6-9wks	N=11	2011

Bopp1:1	Bopp1	health assessment	Plasmodium berghei	survival, post-infection [d] survival 36401	inbred	31	both	8-12wks	N=4	2010

Bopp1:2	Bopp1	health assessment	Plasmodium berghei	terminal body temperature, post-infection [°C] body_temp 36402	inbred	31	both	8-12wks	N=4	2010

Bopp1:3	Bopp1	health assessment	Plasmodium berghei	percentage of parasite-infected erythrocytes in blood [%] parasitemia 36403	inbred	31	both	8-12wks	N=4	2010

Bopp1:4	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in brain relative to all organs tested [%] luciferase_brain 36404	inbred	28	both	8-12wks	N=2	2010

Bopp1:5	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in spleen relative to all organs tested [%] luciferase_spleen 36405	inbred	28	both	8-12wks	N=2	2010

Bopp1:6	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in lungs relative to all organs tested [%] luciferase_lungs 36406	inbred	28	both	8-12wks	N=2	2010

Bopp1:7	Bopp1	health assessment	Plasmodium berghei	percentage of parasites in liver relative to all organs tested [%] luciferase_liver 36407	inbred	28	both	8-12wks	N=2	2010

Brinkmeyer1:1	Brinkmeyer1	body weight	Theiler's murine encephalomyelitis virus	body weight, post infection [g] bw 64401 day 0 day 2 day 4 day 6 day 8 day 10 day 14 day 17 day 22 day 27 (6 more)...	CC	5	both	4wks	N=5	2017

Brinkmeyer1:17	Brinkmeyer1	health assessment	Theiler's murine encephalomyelitis virus	clinical score (0=normal, 6=moribund), post infection [score] clin_score 64417 day 0 day 2 day 4 day 6 day 8 day 12 day 18 day 24 day 29 day 34 (6 more)...	CC	5	both	4wks	N=5	2017

Brinkmeyer1:33	Brinkmeyer1	RNA expression profiling	Theiler's murine encephalomyelitis virus	TMEV transcript abundance (normalized), post infection TMEV 64433 day 7 day 28	CC	4	both	4wks	N=1	2017

Brinkmeyer1:35	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of seconds spent grooming, 10 min test, post infection wk 3 (manual assessment) [s] grooming 64435	CC	5	both	4wks	N=2	2017

Brinkmeyer1:36	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of times mouse reared, 10 min test, post infection wk 3 (manual assessment) [n] activity_rearing 64436	CC	5	both	4wks	N=2	2017

Brinkmeyer1:37	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal movement latency, 30 min test, post infection wk 3 [s] horiz_latency 64437 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:39	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of horizontal movements (beam breaks), 30 min test, post infection wk 3 [n] horiz_activity 64439 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:41	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal distance traveled, 30 min test, post infection wk 3 [cm] horiz_distance 64441 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:43	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent moving horizontally, 30 min test, post infection wk 3 [s] horiz_time 64443 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:45	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	horizontal movement velocity, 30 min test, post infection wk 3 [cm/s] horiz_velocity 64445 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:47	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of vertical plane entries, 30 min test, post infection wk 3 [n] vert_activity 64447 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:49	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of vertical plane episodes, 30 min test, post infection wk 3 [n] vert_episodes 64449 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:51	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent vertical, 30 min test, post infection wk 3 [s] vert_time 64451 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:53	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent resting, 30 min test, post infection wk 3 [s] resting 64453 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:55	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	number of center entries, 30 min test, post infection wk 3 [n] center_entries 64455 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:57	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent in center, 30 min test, post infection wk 3 [s] center_time 64457 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:59	Brinkmeyer1	open field test	Theiler's murine encephalomyelitis virus	time spent in periphery, 30 min test, post infection wk 3 [s] periphery_time 64459 trial 1 trial 2	CC	4	both	4wks	N=2	2017

Brinkmeyer1:61	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of steps included in analysis as measured by DigiGait, post infection day 27, forelimb [n] num_steps_fore 64461 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:63	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of steps included in analysis as measured by DigiGait, post infection day 27, hindlimb [n] num_steps_hind 64463 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:65	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of swing phase (no paw contact with belt) as measured by DigiGait, post infection day 27, forelimb [s] swing_dur_fore 64465 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:67	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of swing phase (no paw contact with belt) as measured by DigiGait, post infection day 27, hindlimb [s] swing_dur_hind 64467 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:69	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in air as measured by DigiGait, post infection day 27, forelimb [%] swing_stride_fore 64469 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:71	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in air as measured by DigiGait, post infection day 27, hindlimb [%] swing_stride_hind 64471 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:73	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of braking phase as measured by DigiGait, post infection day 27, forelimb [s] brake_dur_fore 64473 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:75	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of braking phase as measured by DigiGait, post infection day 27, hindlimb [s] brake_dur_hind 64475 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:77	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in braking phase as measured by DigiGait, post infection day 27, forelimb [%] brake_stride_fore 64477 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:79	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in braking phase as measured by DigiGait, post infection day 27, hindlimb [%] brake_stride_hind 64479 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:81	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in braking phase as measured by DigiGait, post infection day 27, forelimb [%] brake_stance_fore 64481 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:83	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in braking phase as measured by DigiGait, post infection day 27, hindlimb [%] brake_stance_hind 64483 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:85	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of propulsion phase as measured by DigiGait, post infection day 27, forelimb [s] propel_dur_fore 64485 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:87	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of propulsion phase as measured by DigiGait, post infection day 27, hindlimb [s] propel_dur_hind 64487 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:89	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in propulsion phase as measured by DigiGait, post infection day 27, forelimb [%] propel_stride_fore 64489 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:91	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in propulsion phase as measured by DigiGait, post infection day 27, hindlimb [%] propel_stride_hind 64491 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:93	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in propulsion phase as measured by DigiGait, post infection day 27, forelimb [%] propel_stance_fore 64493 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:95	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of stance phase that paw is in propulsion phase as measured by DigiGait, post infection day 27, hindlimb [%] propel_stance_hind 64495 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:97	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in any contact with treadmill belt as measured by DigiGait, post infection day 27, forelimb [%] stance_stride_fore 64497 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:99	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	percentage of total stride duration that paw is in any contact with treadmill belt as measured by DigiGait, post infection day 27, hindlimb [%] stance_stride_hind 64499 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:101	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of swing phase time to stance phase time as measured by DigiGait, post infection day 27, forelimb [ratio] stance_swing_fore 64501 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:103	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of swing phase time to stance phase time as measured by DigiGait, post infection day 27, hindlimb [ratio] stance_swing_hind 64503 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:105	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of one complete stride for one paw (equal to stance and swing durations) as measured by DigiGait, post infection day 27, forelimb [s] stride_dur_fore 64505 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:107	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	duration of one complete stride for one paw (equal to stance and swing durations) as measured by DigiGait, post infection day 27, hindlimb [s] stride_dur_hind 64507 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:109	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of times each second (cadence) that a paw takes a complete stride as measured by DigiGait, post infection day 27, forelimb [n/s] stride_freq_fore 64509 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:111	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	number of times each second (cadence) that a paw takes a complete stride as measured by DigiGait, post infection day 27, hindlimb [n/s] stride_freq_hind 64511 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:113	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	spatial length that a paw traverses through a given stride as measured by DigiGait, post infection day 27, forelimb [cm] stride_length_fore 64513 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:115	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	spatial length that a paw traverses through a given stride as measured by DigiGait, post infection day 27, hindlimb [cm] stride_length_hind 64515 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:117	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length variability as measured by DigiGait, post infection day 27, forelimb [cm] stride_length_var_fore 64517 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:119	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length variability as measured by DigiGait, post infection day 27, hindlimb [cm] stride_length_var_hind 64519 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:121	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length coefficient of variation as measured by DigiGait, post infection day 27, forelimb [%] stride_length_CV_fore 64521 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:123	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride length coefficient of variation as measured by DigiGait, post infection day 27, hindlimb [%] stride_length_CV_hind 64523 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:125	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle that paw makes with long axis of direction of motion of mouse as measured by DigiGait, post infection day 27, forelimb [deg] paw_angle_fore 64525 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:127	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle that paw makes with long axis of direction of motion of mouse as measured by DigiGait, post infection day 27, hindlimb [deg] paw_angle_hind 64527 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:129	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw angle for set of strides recorded as measured by DigiGait, post infection day 27, forelimb [deg] paw_angle_SD_fore 64529 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:131	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw angle for set of strides recorded as measured by DigiGait, post infection day 27, hindlimb [deg] paw_angle_SD_hind 64531 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:133	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal paw area as measured by DigiGait, post infection day 27, forelimb [cm²] paw_area_max_fore 64533 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:135	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal paw area as measured by DigiGait, post infection day 27, hindlimb [cm²] paw_area_max_hind 64535 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:137	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw area for set of strides recorded as measured by DigiGait, post infection day 27, forelimb [cm²] paw_area_SD_fore 64537 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:139	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	standard deviation of paw area for set of strides recorded as measured by DigiGait, post infection day 27, hindlimb [cm²] paw_area_SD_hind 64539 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:141	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of forelimb stepping to fore limb stepping frequency (coordination metric) as measured by DigiGait, post infection day 27, forelimb [ratio] gait_symmetry_fore 64541 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:143	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of forelimb stepping to hind limb stepping frequency (coordination metric) as measured by DigiGait, post infection day 27, hindlimb [ratio] gait_symmetry_hind 64543 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:145	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during braking phase as measured by DigiGait, post infection day 27, forelimb [cm²/s] max_area_break_fore 64545 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:147	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during braking phase as measured by DigiGait, post infection day 27, hindlimb [cm²/s] max_area_break_hind 64547 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:149	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during propulsion phase as measured by DigiGait, post infection day 27, forelimb [cm²/s] max_area_propuls_fore 64549 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:151	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	maximal rate of change in paw area in contact with treadmill belt during propulsion phase as measured by DigiGait, post infection day 27, hindlimb [cm²/s] max_area_propuls_hind 64551 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:153	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	overlap extent of ipsilateral fore and hind paws as measured by DigiGait, post infection day 27, forelimb [cm] overlap_distance_fore 64553 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:155	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	overlap extent of ipsilateral fore and hind paws as measured by DigiGait, post infection day 27, hindlimb [cm] overlap_distance_hind 64555 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:157	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	extent of overlap between ipsilateral fore and hind paws during full stance (balance metric) as measured by DigiGait, post infection day 27, forelimb [cm] paw_placement_fore 64557 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:159	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	extent of overlap between ipsilateral fore and hind paws during full stance (balance metric) as measured by DigiGait, post infection day 27, hindlimb [cm] paw_placement_hind 64559 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:161	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	gait variability metric as measured by DigiGait, post infection day 27, forelimb ataxia_coefficient_fore 64561 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:163	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	gait variability metric as measured by DigiGait, post infection day 27, hindlimb ataxia_coefficient_hind 64563 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:165	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through transverse midline of mouse (kinetics metric) as measured by DigiGait, post infection day 27, forelimb [cm] midline_distance_fore 64565 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:167	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through transverse midline of mouse (kinetics metric) as measured by DigiGait, post infection day 27, hindlimb [cm] midline_distance_hind 64567 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:169	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through axis of mouse (kinetics metric) as measured by DigiGait, post infection day 27, forelimb [cm] axis_distance_fore 64569 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:171	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	distance between centroid of a paw at peak stance and a reference line drawn through axis of mouse (kinetics metric) as measured by DigiGait, post infection day 27, hindlimb [cm] axis_distance_hind 64571 left right	CC	4	both	4wks	N=1	2017

Brinkmeyer1:173	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	perpendicular distance between centroids of either set of axial paws during peak stance as measured by DigiGait, post infection day 27 [cm] stance_width 64573 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:175	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stance width coefficient of variation as measured by DigiGait, post infection day 27 [%] stance_width_CV 64575 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:177	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	ratio of left and right stance durations as measured by DigiGait, post infection day 27 [ratio] stance_factor 64577 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:179	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	stride width variability as measured by DigiGait, post infection day 27 [cm] stride_width_var 64579 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:181	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	angle made between left and right paws as a function of stride length and stance width as measured by DigiGait, post infection day 27 [deg] step_angle 64581 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:183	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	step angle variability (standard deviation of step angle for set of strides recorded) as measured by DigiGait, post infection day 27 [deg] step_angle_SD 64583 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:185	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	step angle coefficient of variation as measured by DigiGait, post infection day 27 [%] step_angle_CV 64585 forelimb hindlimb	CC	4	both	4wks	N=1	2017

Brinkmeyer1:187	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	length of forelimb steps as measured by foot print analysis, post infection [cm] length_fore 64587 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:194	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	width of forelimb steps as measured by foot print analysis, post infection [cm] width_fore 64594 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:201	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	length of hindlimb steps as measured by foot print analysis, post infection [cm] length_hind 64601 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:208	Brinkmeyer1	gait analysis	Theiler's murine encephalomyelitis virus	width of hindlimb steps as measured by foot print analysis, post infection [cm] width_hind 64608 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12 wk 13	CC	5	both	4wks	N=2	2017

Brinkmeyer1:215	Brinkmeyer1	rotarod	Theiler's murine encephalomyelitis virus	time to fall from accelerating rotarod, post infection wk 7 [s] rotarod 64615 trial 1 trial 2 trial 3 trial 4 trial 5 trial 6 trial 7 trial 8 trial 9	CC	5	both	4wks	N=2	2017

Brockmann1:11	Brockmann1	organ weights	(none)	weight of spleen [mg] Spleen 21311	QTL population		both	6wks	N=138	2009

Brockmann1:28	Brockmann1	organ weights	(none)	weight of spleen [mg] spleen 21508	QTL population		both	6wks	N=201	2009

CGDpheno1:1	CGDpheno1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 31801	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:5	CGDpheno1	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctNEUT 31805	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:6	CGDpheno1	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pctLYMP 31806	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:7	CGDpheno1	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctMONO 31807	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:8	CGDpheno1	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 31808	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno3:6	CGDpheno3	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 43906	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:7	CGDpheno3	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pctLYMP 43907	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:8	CGDpheno3	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctNEUT 43908	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:9	CGDpheno3	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctMONO 43909	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:10	CGDpheno3	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctBASO 43910	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:11	CGDpheno3	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 43911	CC diallel w/par	62	both	7wks	N=5	2012

CGDpheno3:12	CGDpheno3	complete blood count	(none)	large unstained cells (LUC; percentage of total WBC) [%] pctLUC 43912	CC diallel w/par	62	both	7wks	N=5	2012

Chen1:1	Chen1	immune cell quantification	(none)	percentage of total TCRβ+ cells that are invariant NK T cells, peripheral blood [%] pct_iNKT_T_pb 52301	inbred	38	m	8-10wks	N=4	2011

Chen1:2	Chen1	immune cell quantification	(none)	percentage of invariant NK T cells that express CD4, peripheral blood [%] pct_iNKT_CD4_pb 52302	inbred	34	m	8-10wks	N=4	2011

Chen1:3	Chen1	immune cell quantification	(none)	percentage of total TCRβ+ cells that are invariant NK T cells, spleen [%] pct_iNKT_T_spleen 52303	inbred	38	m	8-10wks	N=4	2011

Chen1:4	Chen1	immune cell quantification	(none)	percentage of invariant NK T cells that express CD4, spleen [%] pct_iNKT_CD4_spleen 52304	inbred	35	m	8-10wks	N=4	2011

Chen1:5	Chen1	immune cell quantification	(none)	peripheral blood to spleen ratio of invariant NK T cells [ratio] iNKT_pb_spl_ratio 52305	inbred	38	m	8-10wks	N=4	2011

Chen1:6	Chen1	immune cell quantification	(none)	percentage of total TCRβ^hi cells that are invariant NK T cells, thymus [%] pct_iNKT_T_thymus 52306	inbred	38	m	8-10wks	N=4	2011

Chen1:7	Chen1	immune cell quantification	(none)	percentage of invariant NK T cells that express CD4, thymus [%] pct_iNKT_CD4_thymus 52307	inbred	35	m	8-10wks	N=4	2011

Chen1:8	Chen1	immune cell quantification	(none)	peripheral blood to thymus ratio of invariant NK T cells [ratio] iNKT_pb_thy_ratio 52308	inbred	38	m	8-10wks	N=4	2011

Chesler2:11	Chesler2	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC 43413	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:12	Chesler2	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYM 43414	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:13	Chesler2	complete blood count	(none)	lymphocyte differential (LYM; percentage of viable WBC) [%] pct_LYM 43415	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:14	Chesler2	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 43416	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:15	Chesler2	complete blood count	(none)	monocyte differential (MONO; percentage of viable WBC) [%] pct_MONO 43417	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:16	Chesler2	complete blood count	(none)	granulocyte count (GRA; units per volume x 10³) [n/µL] GRA 43418	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:17	Chesler2	complete blood count	(none)	granulocyte differential (GRA; percentage of total viable WBC) [%] pct_GRA 43419	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler2:18	Chesler2	complete blood count	(none)	eosinophil differential (EOS; percentage of viable WBC) [%] pct_EOS 43420	CC diallel w/par	48	both	7-15wks	N=2	2011

Chesler3:13	Chesler3	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC 43513	CC pre w/par	199	both	7-15wks	N=1	2011

Chesler3:14	Chesler3	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYM 43514	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:15	Chesler3	complete blood count	(none)	lymphocyte differential (LYM; percentage of viable WBC) [%] pct_LYM 43515	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:16	Chesler3	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 43516	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:17	Chesler3	complete blood count	(none)	monocyte differential (MONO; percentage of viable WBC) [%] pct_MONO 43517	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:18	Chesler3	complete blood count	(none)	granulocyte count (GRA; units per volume x 10³) [n/µL] GRA 43518	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:19	Chesler3	complete blood count	(none)	granulocyte differential (GRA; percentage of total viable WBC) [%] pct_GRA 43519	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:20	Chesler3	complete blood count	(none)	eosinophil differential (EOS; percentage of viable WBC) [%] pct_EOS 43520	CC pre w/par	198	both	7-15wks	N=1	2011

Chesler3:99	Chesler3	organ weights	(none)	spleen weight [g] spleen_wt 43599	CC pre w/par	263	both	7-15wks	N=2	2011

Cheverud1:21	Cheverud1	organ weights	high-fat diet	spleen weight as percentage of body weight [%] spleenwt_adj 17822 control diet high-fat diet	LGXSM w/par	17	both	20-30wks	N=8	2004

Clemens1:1	Clemens1	health assessment	ultraviolet light	UV-induced immunosuppression of contact hypersensitivity [%] suppression 10601	QTL population		both	9-30wks	N=67	2000

Collins1:2	Collins1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 45102	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:3	Collins1	complete blood count	(none)	lymphocyte count (LYM; per volume x 10³) [n/µL] LYM 45103	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:4	Collins1	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] LYM_pct 45104	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:5	Collins1	complete blood count	(none)	neutrophil count (NEUT; per volume x 10³) [n/µL] NEUT 45105	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:6	Collins1	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] NEUT_pct 45106	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:7	Collins1	complete blood count	(none)	monocyte count (MONO; per volume x 10³) [n/µL] MONO 45107	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:8	Collins1	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] MONO_pct 45108	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:9	Collins1	complete blood count	(none)	eosinophil count (EOS; per volume x 10³) [n/µL] EOS 45109	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:10	Collins1	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] EOS_pct 45110	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:11	Collins1	complete blood count	(none)	basophil count (BASO; per volume x 10³) [n/µL] BASO 45111	CC pre w/par	138	m	10-14wks	N=1	2012

Collins1:12	Collins1	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] BASO_pct 45112	CC pre w/par	138	m	10-14wks	N=1	2012

Cowell1:1	Cowell1	hormone quantification	Staphylococcus aureus	fold-change in serum IL-6 levels 24h post-infection compared to controls [ratio] IL6 49001	inbred	13	f	8wks	N=3	2012

Cowell1:2	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from peritoneal fluid 24h post-infection (x 10³) (CFU/mL) [log(n/mL)] peritoneal_CFU 49002	inbred	13	f	8wks	N=5	2012

Cowell1:3	Cowell1	in vitro assay	Staphylococcus aureus	log₁₀ bacterial colony count from kidney 24h post-infection (CFU/g) [log(n/g)] kidney_CFU 49003	inbred	13	f	8wks	N=6	2012

Cowell1:4	Cowell1	health assessment	Staphylococcus aureus	median survival time, max time 104h [h] median_survival 49004	inbred	13	f	8wks	N=11	2012

Cowell1:5	Cowell1	health assessment	Staphylococcus aureus	percent survival, max time 104h [%] pct_survival 49005	inbred	13	f	8wks	N=11	2012

Deschepper1:15	Deschepper1	organ weights	(none)	thymus weight [mg] thymus 10415 weight normalized to bw	inbred	13	both	10wks	N=10	2004

Dietrich1:1	Dietrich1	in vitro assay	Bacillus anthracis lethal toxin	susceptibility to Bacillus anthracis (0=susceptible, 1=resistant) [designation] anthrax_lethal_toxin 1501	inbred	50	f	6-8wks*		1998

Donahue5:1	Donahue5	immune cell quantification	(none)	neutrophil differential (percentage of viable WBC) [%] pct_NEUT 41401	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:2	Donahue5	immune cell quantification	(none)	eosinophil differential (percentage of viable WBC) [%] pct_EOS 41402	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:3	Donahue5	immune cell quantification	(none)	monocyte differential (percentage of viable WBC) [%] pct_MONO 41403	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:4	Donahue5	immune cell quantification	(none)	inflammatory monocytes (percentage of viable WBC) [%] pct_MONO_inflam 41404	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:5	Donahue5	immune cell quantification	(none)	resident monocytes (percentage of viable WBC) [%] pct_MONO_resident 41405	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:6	Donahue5	immune cell quantification	(none)	B cells (percentage of viable WBC) [%] pct_B_cells 41406	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:7	Donahue5	immune cell quantification	(none)	natural killer (NK) cells (percentage of viable WBC) [%] pct_NK_cells 41407	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:8	Donahue5	immune cell quantification	(none)	mature natural killer (NK) cells (percentage of viable WBC) [%] pct_NK_mature 41408	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:9	Donahue5	immune cell quantification	(none)	T cells (percentage of viable WBC) [%] pct_T_cells 41409	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:10	Donahue5	immune cell quantification	(none)	CD4 T cells (percentage of viable WBC) [%] pct_CD4 41410	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue5:12	Donahue5	immune cell quantification	(none)	CD8 T cells (percentage of viable WBC) [%] pct_CD8 41412	B6.A consomic w/par	22	both	7wks	N=8	2011

Donahue6:1	Donahue6	immune cell quantification	(none)	neutrophil differential (percentage of viable WBC) [%] pct_NEUT 41501	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:2	Donahue6	immune cell quantification	(none)	eosinophil differential (percentage of viable WBC) [%] pct_EOS 41502	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:3	Donahue6	immune cell quantification	(none)	monocyte differential (percentage of viable WBC) [%] pct_MONO 41503	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:4	Donahue6	immune cell quantification	(none)	inflammatory monocytes (percentage of viable WBC) [%] pct_MONO_inflam 41504	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:5	Donahue6	immune cell quantification	(none)	resident monocytes (percentage of viable WBC) [%] pct_MONO_resident 41505	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:6	Donahue6	immune cell quantification	(none)	B cells (percentage of viable WBC) [%] pct_B_cells 41506	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:7	Donahue6	immune cell quantification	(none)	natural killer (NK) cells (percentage of viable WBC) [%] pct_NK_cells 41507	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:8	Donahue6	immune cell quantification	(none)	mature natural killer (NK) cells (percentage of viable WBC) [%] pct_NK_mature 41508	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:9	Donahue6	immune cell quantification	(none)	T cells (percentage of viable WBC) [%] pct_T_cells 41509	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:10	Donahue6	immune cell quantification	(none)	CD4 T cells (percentage of viable WBC) [%] pct_CD4 41510	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue6:11	Donahue6	immune cell quantification	(none)	CD8 T cells (percentage of viable WBC) [%] pct_CD8 41511	B6.PWD consomic w/par	28	both	7wks	N=8	2011

Donahue7:1	Donahue7	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41601	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:2	Donahue7	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41602	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue7:3	Donahue7	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41603	B6.A consomic w/par	22	both	9wks	N=8	2012

Donahue8:1	Donahue8	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 41701	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:2	Donahue8	immunoglobulin quantification	(none)	immunoglobulin G (plasma IgG) [µg/mL] IgG 41702	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Donahue8:3	Donahue8	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 41703	B6.PWD consomic w/par	28	both	9wks	N=8	2011

Eumorphia1:16	Eumorphia1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 23916	inbred	6	both	12wks	N=23	2007

Eumorphia1:26	Eumorphia1	complete blood count	(none)	lymphocyte count (LYMP; units per volume x 10³) [n/µL] LYMP 23926	inbred	4	both	12wks	N=15	2007

Eumorphia1:27	Eumorphia1	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 23927	inbred	4	both	12wks	N=15	2007

Eumorphia7:1	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin M (serum IgM) [µg/mL] IgM 29601	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:2	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G3 (serum IgG3) [µg/mL] IgG3 29602	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:3	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G1 (serum IgG1) [µg/mL] IgG1 29603	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:4	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2b (serum IgG2b) [µg/mL] IgG2b 29604	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:5	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin G2a (serum IgG2a) [µg/mL] IgG2a 29605	inbred	6	both	9-12wks	N=5	2008

Eumorphia7:6	Eumorphia7	immunoglobulin quantification	(none)	immunoglobulin A (serum IgA) [µg/mL] IgA 29606	inbred	6	both	9-12wks	N=5	2008

Farmer1:1	Farmer1	histopathology	(none)	severity of lesions in cecum [score] CecumSeverity 11301	QTL population		both	6wks	N=206	2001

Farmer1:2	Farmer1	histopathology	(none)	hyperplasia of cecum [score] CecumHyperplasia 11302	QTL population		both	6wks	N=206	2001

Farmer1:3	Farmer1	histopathology	(none)	ulceration in cecum [score] CecumUlceration 11303	QTL population		both	6wks	N=206	2001

Farmer1:4	Farmer1	histopathology	(none)	percentage of cecum damaged area [%] CecumDA 11304	QTL population		both	6wks	N=206	2001

Farmer1:5	Farmer1	histopathology	(none)	sum of cecum severity, hyperplasia, ulceration and damaged area scores [score] CecumTotalScore 11305	QTL population		both	6wks	N=206	2001

Farmer1:6	Farmer1	histopathology	(none)	percentage of proximal colon damaged area [%] ProxDA 11306	QTL population		both	6wks	N=206	2001

Farmer1:7	Farmer1	histopathology	(none)	severity of lesions in proximal colon [score] ProxSeverity 11307	QTL population		both	6wks	N=206	2001

Farmer1:8	Farmer1	histopathology	(none)	hyperplasia of proximal colon [score] ProxHyperplasia 11308	QTL population		both	6wks	N=206	2001

Farmer1:9	Farmer1	histopathology	(none)	ulceration in proximal colon [score] ProxUlceration 11309	QTL population		both	6wks	N=206	2001

Farmer1:10	Farmer1	histopathology	(none)	percentage of damaged area in mid colon [%] MidDA 11310	QTL population		both	6wks	N=206	2001

Farmer1:11	Farmer1	histopathology	(none)	severity of lesions in mid colon [score] MidSeverity 11311	QTL population		both	6wks	N=206	2001

Farmer1:12	Farmer1	histopathology	(none)	hyperplasia of mid colon [score] MidHyperplasia 11312	QTL population		both	6wks	N=206	2001

Farmer1:13	Farmer1	histopathology	(none)	ulcers and crypts frequency score [score] MidUlceration 11313	QTL population		both	6wks	N=206	2001

Farmer1:14	Farmer1	histopathology	(none)	percentage of damaged area in distal colon [%] DistalDA 11314	QTL population		both	6wks	N=206	2001

Farmer1:15	Farmer1	histopathology	(none)	severity of lesions in distal colon [score] DistalSeverity 11315	QTL population		both	6wks	N=206	2001

Farmer1:16	Farmer1	histopathology	(none)	hyperplasia of distal colon [score] DistalHyperplasia 11316	QTL population		both	6wks	N=206	2001

Farmer1:17	Farmer1	histopathology	(none)	ulceration in distal colon [score] DistalUlceration 11317	QTL population		both	6wks	N=206	2001

Farmer1:18	Farmer1	histopathology	(none)	proximal colon score [score] ProximalColon 11318	QTL population		both	6wks	N=206	2001

Farmer1:19	Farmer1	histopathology	(none)	middle colon score [score] MiddleColon 11319	QTL population		both	6wks	N=206	2001

Farmer1:20	Farmer1	histopathology	(none)	distal colon score [score] DistalColon 11320	QTL population		both	6wks	N=206	2001

Farmer1:21	Farmer1	histopathology	(none)	total score [score] ColonTotalScore 11321	QTL population		both	6wks	N=206	2001

Farmer1:23	Farmer1	organ weights	(none)	spleen weight [g] SpleenWeight 11323	QTL population		both	6wks	N=206	2001

Farmer1:24	Farmer1	organ weights	(none)	spleen/body weight ratio [%] SplBW 11324	QTL population		both	6wks	N=206	2001

Farmer1:25	Farmer1	organ weights	(none)	mesenteric lymph node (MLN) weight [g] MLNWeight 11325	QTL population		both	6wks	N=206	2001

Farmer1:26	Farmer1	organ weights	(none)	MLN/body weight ratio [%] MLNBW 11326	QTL population		both	6wks	N=206	2001

Farmer1:34	Farmer1	immune cell quantification	(none)	percentage of viable CD4⁺ T cells in 150 µl collected blood [%] CD4 11334	QTL population		both	6wks	N=206	2001

Farmer1:35	Farmer1	immune cell quantification	(none)	percentage of viable CD8⁺ T cells in 150 µl collected blood [%] CD8 11335	QTL population		both	6wks	N=206	2001

Farmer1:36	Farmer1	immune cell quantification	(none)	percentage of viable B220⁺ B cells in 150 µl collected blood [%] B220 11336	QTL population		both	6wks	N=206	2001

Farmer1:37	Farmer1	immune cell quantification	(none)	percentage of viable IgM⁺ B cells in 150 µl collected blood [%] lgM 11337	QTL population		both	6wks	N=206	2001

Farmer1:38	Farmer1	immune cell quantification	(none)	percentage of macrophages in 150 µl collected blood [%] Macrophages 11338	QTL population		both	6wks	N=206	2001

Farmer1:39	Farmer1	immune cell quantification	(none)	percentage of viable granulocytes in 150 µl collected blood [%] Granulocytes 11339	QTL population		both	6wks	N=206	2001

Ferris1:3	Ferris1	health assessment	influenza A (H1N1) virus	clinical score, day 4 post-infection (score 0-4) [score] clinical_score 47603	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:5	Ferris1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection index (0=susceptible; 1= resistant) [score] susceptibility_index 47605	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:6	Ferris1	in vitro assay	influenza A (H1N1) virus	viral replication log titer, day 4 post-infection (lung) [n] titer 47606	CC pre w/par	162	f	8-16wks	N=1	2012

Ferris1:7	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway inflammation, day 4 post-infection (score 0-3) [score] airway_inflam 47607	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:8	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway neutrophils, day 4 post-infection (score 0-3) [score] airway_neut 47608	CC pre w/par	140	f	8-16wks	N=1	2012

Ferris1:9	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced airway damage, day 4 post-infection (score 0-3) [score] airway_damage 47609	CC pre w/par	160	f	8-16wks	N=1	2012

Ferris1:10	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced vascular inflammation (lung), day 4 post-infection (score 0-3) [score] vascular_inflam 47610	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:11	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced alveolar inflammation, day 4 post-infection (score 0-3) [score] alveolar_inflam 47611	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:12	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced alveolar damage, day 4 post-infection (score 0-3) [score] alveolar_damage 47612	CC pre w/par	161	f	8-16wks	N=1	2012

Ferris1:13	Ferris1	histopathology	influenza A (H1N1) virus	virus-induced pulmonary edema, day 4 post-infection (score 0-3) [score] pulmonary_edema 47613	CC pre w/par	138	f	8-16wks	N=1	2012

Gatti2:1	Gatti2	complete blood count	(none)	white blood cell counts [thousands/µL] WBC 28901	DO population		both	10-12wks	N=371	2014

Gatti2:2	Gatti2	complete blood count	(none)	neutrophil counts [n/µL] NEUR 28902	DO population		both	10-12wks	N=371	2014

GMC15:1	GMC15	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 56401	inbred w/CC8	8	both	20-21wks	N=11	2018

GMC20:2	GMC20	immunoglobulin quantification	(none)	immunoglobulin M (plasma IgM) [µg/mL] IgM 56902 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:4	GMC20	immunoglobulin quantification	(none)	immunoglobulin A (plasma IgA) [µg/mL] IgA 56904 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=5	2018

GMC20:6	GMC20	immunoglobulin quantification	(none)	immunoglobulin G1 (plasma IgG1) [µg/mL] IgG1 56906 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:8	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2a (plasma IgG2a) [µg/mL] IgG2a 56908 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:10	GMC20	immunoglobulin quantification	(none)	immunoglobulin G2b (plasma IgG2b) [µg/mL] IgG2b 56910 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=4	2018

GMC20:12	GMC20	immunoglobulin quantification	(none)	immunoglobulin G3 (plasma IgG3) [µg/mL] IgG3 56912 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC20:14	GMC20	immunoglobulin quantification	(none)	immunoglobulin E (plasma IgE) [ng/mL] IgE 56914 age 16-17wks 20-21wks	inbred w/CC8	8	both		N=6	2018

GMC21:5	GMC21	organ weights	(none)	spleen weight [g] spleen_wt 57005	inbred w/CC8	8	both	21wks	N=11	2018

Graham1:1	Graham1	body weight	West Nile virus	body weight, post infection [g] bw 63301 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...	CC RIX	5	m	8-10wks	N=12	2015

Graham1:15	Graham1	health assessment	West Nile virus	clinical score (0=healthy, 1=lethargic, 2=altered gait, 3=no movement, 4=moribund), post infection [score] clin_score 63315 day 0 day 3 day 6 day 8 day 9 day 10 day 11 day 12 day 13 day 14 (4 more)...	CC RIX	5	m	8-10wks	N=12	2015

Graham1:29	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in brain, post infection [%] CD4_brain 63329 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:33	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD4+ in spleen, post infection [%] CD4_spleen 63333 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:37	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the brain, post infection [%] Treg_brain 63337 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:41	Graham1	immune cell quantification	West Nile virus	percentage of CD4+ T cells that are Foxp3+ in the spleen, post infection [%] Treg_spleen 63341 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:45	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in brain, post infection [%] CD8_brain 63345 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:49	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are CD8+ in spleen, post infection [%] CD8_spleen 63349 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:53	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in brain, post infection [%] NS4b_brain 63353 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:57	Graham1	immune cell quantification	West Nile virus	percentage of CD3+ T cells that are NS4b+ in spleen, post infection [%] NS4b_spleen 63357 day 7 day 12 day 21 day 28	CC RIX	2	m	8-10wks	N=3	2015

Graham1:61	Graham1	immunoglobulin quantification	West Nile virus	virus-specific IgM in serum, post infection [ng/mL] WNV_IgM 63361 day 7 day 12 day 21 day 28	CC RIX	5	m	8-10wks	N=3	2015

Graham1:65	Graham1	RNA expression profiling	West Nile virus	virus in brain, fold change compared to matched control, post infection WNV_brain 63365 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:68	Graham1	RNA expression profiling	West Nile virus	virus in kidney, fold change compared to matched control, post infection WNV_kidney 63368 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:72	Graham1	RNA expression profiling	West Nile virus	virus in spleen, fold change compared to matched control, post infection WNV_spleen 63372 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:76	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in brain, fold change compared to matched control, post infection Ifnb1_brain 63376 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:79	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in kidney, fold change compared to matched control, post infection Ifnb1_kidney 63379 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:83	Graham1	RNA expression profiling	West Nile virus	Ifnb1 gene expression in spleen, fold change compared to matched control, post infection Ifnb1_spleen 63383 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:87	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in brain, fold change compared to matched control, post infection Ifit1_brain 63387 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:90	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in kidney, fold change compared to matched control, post infection Ifit1_kidney 63390 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham1:94	Graham1	RNA expression profiling	West Nile virus	Ifit1 gene expression in spleen, fold change compared to matched control, post infection Ifit1_spleen 63394 day 2 day 4 day 7 day 12	CC RIX	5	m	8-10wks	N=1	2015

Graham2:3	Graham2	colony observation	SARS-CoV	body weight loss and survival score (1=0-5% loss, 2=5-15% loss, 3=greater than 15% loss and death) [score] weight_score 113787	CC RIX	117	f	8-10wks		2021

Graham2:6	Graham2	in vitro assay	SARS-CoV	lung viral load titer (log10(x+1)), post infection [log(n)] log_titer 113790 post infection: day 2 day 4	CC RIX	111	f	8-10wks		2021

Graham3:9	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4+ T cells [%] CD4_pos_tot 113800	CC RIX	102	m	8-10wks	N=4	2021

Graham3:10	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Foxp3+ (Treg) [%] Tregs 113801	CC RIX	102	m	8-10wks	N=4	2021

Graham3:11	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD29+ [%] Treg_CD29_pos 113802	CC RIX	102	m	8-10wks	N=4	2021

Graham3:12	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD44hi [%] Treg_CD44_hi 113803	CC RIX	102	m	8-10wks	N=4	2021

Graham3:13	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CD73+ [%] Treg_CD73_pos 113804	CC RIX	102	m	8-10wks	N=4	2021

Graham3:14	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CTLA-4+ [%] Treg_CTLA4_pos 113805	CC RIX	102	m	8-10wks	N=4	2021

Graham3:15	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are CXCR3+ [%] Treg_CXCR3_pos 113806	CC RIX	102	m	8-10wks	N=4	2021

Graham3:16	Graham3	immune cell quantification	(none)	percentage of splenic Treg cells that are ICOS+ (inducible costimulator) [%] Treg_ICOS_pos 113807	CC RIX	102	m	8-10wks	N=4	2021

Graham3:21	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells (memory precursor panel) [%] mp_CD3_pos 113812	CC RIX	92	m	8-10wks	N=4	2021

Graham3:22	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ (memory precursor panel) [%] mp_CD3_pos_CD8_pos 113813	CC RIX	92	m	8-10wks	N=4	2021

Graham3:23	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD44+ (memory precursor panel) [%] mp_CD8_pos_CD44_pos 113814	CC RIX	91	m	8-10wks	N=4	2021

Graham3:24	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD62L- (memory precursor panel) [%] mp_CD8_pos_CD62L_neg 113815	CC RIX	76	m	8-10wks	N=3	2021

Graham3:25	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are Ki67+ (memory precursor panel) [%] mp_CD8_pos_Ki67_pos 113816	CC RIX	92	m	8-10wks	N=4	2021

Graham3:26	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ (memory precursor panel) [%] mp_CD3_pos_CD4_pos 113817	CC RIX	92	m	8-10wks	N=4	2021

Graham3:27	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD44+ (memory precursor panel) [%] mp_CD4_pos_CD44_pos 113818	CC RIX	91	m	8-10wks	N=4	2021

Graham3:28	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD62L- (memory precursor panel) [%] mp_CD4_pos_CD62L_neg 113819	CC RIX	73	m	8-10wks	N=3	2021

Graham3:29	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Ki67+ (memory precursor panel) [%] mp_CD4_pos_Ki67_pos 113820	CC RIX	92	m	8-10wks	N=4	2021

Graham3:34	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells (memory panel) [%] mem_CD3_pos 113825	CC RIX	68	m	8-10wks	N=3	2021

Graham3:35	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ (memory panel) [%] mem_CD3_pos_CD8_pos 113826	CC RIX	68	m	8-10wks	N=3	2021

Graham3:36	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD44+ (memory panel) [%] mem_CD8_pos_CD44_pos 113827	CC RIX	73	m	8-10wks	N=3	2021

Graham3:37	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are CD62L- (memory panel) [%] mem_CD8_pos_CD62L_neg 113828	CC RIX	68	m	8-10wks	N=3	2021

Graham3:38	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are Ki67+ (memory panel) [%] mem_CD8_pos_Ki67_pos 113829	CC RIX	73	m	8-10wks	N=3	2021

Graham3:39	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ (memory panel) [%] mem_CD3_pos_CD4_pos 113830	CC RIX	68	m	8-10wks	N=3	2021

Graham3:40	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD44+ (memory panel) [%] mem_CD4_pos_CD44_pos 113831	CC RIX	73	m	8-10wks	N=3	2021

Graham3:41	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are CD62L- (memory panel) [%] mem_CD4_pos_CD62L_neg 113832	CC RIX	68	m	8-10wks	N=3	2021

Graham3:42	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Ki67+ (memory panel) [%] mem_CD4_pos_Ki67_pos 113833	CC RIX	73	m	8-10wks	N=3	2021

Graham3:47	Graham3	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3+ T cells following stimulation with anti-CD3 and anti CD28 [%] ics_CD3_pos 113838	CC RIX	102	m	8-10wks	N=4	2021

Graham3:48	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD8+ following stimulation with anti-CD3 and anti-CD28 [%] ics_CD3_pos_CD8_pos 113839	CC RIX	102	m	8-10wks	N=4	2021

Graham3:49	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IL17_pos 113840	CC RIX	102	m	8-10wks	N=4	2021

Graham3:50	Graham3	immune cell quantification	(none)	percentage of splenic CD8+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD8_pos_IGNg_pos 113841	CC RIX	102	m	8-10wks	N=4	2021

Graham3:51	Graham3	immune cell quantification	(none)	percentage of splenic CD3+ T cells that are CD4+ following stimulation with anti-CD3 and anti-CD28 [%] ics_CD3_pos_CD4_pos 113842	CC RIX	102	m	8-10wks	N=4	2021

Graham3:52	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IL-17+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IL17_pos 113843	CC RIX	102	m	8-10wks	N=4	2021

Graham3:53	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are IFNg+ by intracellular cytokine staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_IFNg_pos 113844	CC RIX	102	m	8-10wks	N=4	2021

Graham3:54	Graham3	immune cell quantification	(none)	percentage of splenic CD4+ T cells that are Tbet+ (transcription factor) by intracellular staining following stimulation with anti-CD3 and anti-CD28 [%] ics_CD4_pos_Tbet_pos 113845	CC RIX	92	m	8-10wks	N=4	2021

Graubert1:1	Graubert1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 11601	inbred	20	both	9wks	N=12	2006

Graubert1:2	Graubert1	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 11602	inbred	20	both	9wks	N=12	2006

Graubert1:3	Graubert1	complete blood count	(none)	lymphocyte count (LYMP; units per volume x 10³) [n/µL] LYMP 11603	inbred	20	both	9wks	N=12	2006

Graubert1:4	Graubert1	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pct_NEUT 11604	inbred	20	both	9wks	N=12	2006

Graubert1:5	Graubert1	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pct_LYMP 11605	inbred	20	both	9wks	N=12	2006

Gros1:1	Gros1	in vitro assay	Candida albicans	kidney fungal load 48h post-infection, colony-forming units (log₁₀ CFU per kidney) [log(n)] fungal_load 38501	inbred	23	f	8-12wks	N=9	2011

Gros1:2	Gros1	in vitro assay	Candida albicans	susceptibility to C. albicans based on fungal load (0=susceptible; 1=resistant) [designation] susceptibility 38502	inbred	23	f	8-12wks	N=9	2011

Gros2:1	Gros2	microscopy	Plasmodium chabaudi	percentage of parasite-infected erythrocytes in blood [%] parasitemia 49301	inbred	25	both	8-10wks	N=5	2012

Gros2:2	Gros2	health assessment	Plasmodium chabaudi	percent survival post-infection (max=21d) [%] survival 49302	inbred	25	both	8-10wks	N=5	2012

Gros2:3	Gros2	health assessment	Plasmodium chabaudi	response to infection (0=susceptible, 0.5=intermediate, 1=resistant) [designation] resistance 49303	inbred	25	both	8-10wks	N=5	2012

Hackstein1:1	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage total leukocyte count (x 10³) [n] BAL 49101	inbred	5	m	7-11wks	N=5	2012

Hackstein1:2	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage macrophages (percentage of leukocytes) [%] BAL_MAC 49102	inbred	5	m	7-11wks	N=5	2012

Hackstein1:3	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage dendritic cells (percentage of CD45+ cells) [%] DC 49103	inbred	5	m	7-11wks	N=9	2012

Hackstein1:4	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage plasmacytoid dendritic cells (percentage of CD45+ cells) [%] DC_plasmacytoid 49104	inbred	5	m	7-11wks	N=9	2012

Hackstein1:5	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage monocytic dendritic cells (percentage of CD45+ cells) [%] DC_monocytic 49105	inbred	5	m	7-11wks	N=9	2012

Hackstein1:6	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD103+ dendritic cells (percentage of CD45+ cells) [%] DC_103 49106	inbred	5	m	7-11wks	N=9	2012

Hackstein1:7	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD11b^hi MHC^hi dendritic cells (percentage of CD45+ cells) [%] DC_11b 49107	inbred	5	m	7-11wks	N=9	2012

Hackstein1:8	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage Siglec F+ F4/80+ macrophages (percentage of CD45+ cells) [%] MAC 49108	inbred	5	m	7-11wks	N=9	2012

Hackstein1:9	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage neutrophils (percentage of CD45+ cells) [%] NEUT 49109	inbred	5	m	7-11wks	N=9	2012

Hackstein1:10	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage eosinophils (percentage of CD45+ cells) [%] EOS 49110	inbred	5	m	7-11wks	N=9	2012

Hackstein1:11	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage Lin^neg CD90+ innate cells (percentage of CD45+ cells) [%] Lin_neg_90_plus 49111	inbred	5	m	7-11wks	N=6	2012

Hackstein1:12	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage Lin^neg CD90^- innate cells (percentage of CD45+ cells) [%] Lin_neg_90_neg 49112	inbred	5	m	7-11wks	N=6	2012

Hackstein1:13	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD19+ B cells (percentage of CD45+ cells) [%] B_cells 49113	inbred	5	m	7-11wks	N=8	2012

Hackstein1:14	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ T cells (percentage of CD45+ cells) [%] T_CD3 49114	inbred	5	m	7-11wks	N=9	2012

Hackstein1:15	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD8+ T cells (percentage of CD45+ cells) [%] T_CD8 49115	inbred	5	m	7-11wks	N=9	2012

Hackstein1:16	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD4+ T cells (percentage of CD45+ cells) [%] T_CD4 49116	inbred	5	m	7-11wks	N=9	2012

Hackstein1:17	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD4+ CD25+ T cells (percentage of CD45+ cells) [%] T_CD4_25 49117	inbred	5	m	7-11wks	N=8	2012

Hackstein1:18	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD4+ CD25^hi Treg cells (percentage of CD45+ cells) [%] T_CD4_25hi 49118	inbred	5	m	7-11wks	N=5	2012

Hackstein1:19	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD4+ CD25^hi Foxp3+ Treg cells (percentage of CD45+ cells) [%] T_CD4_foxp3 49119	inbred	5	m	7-11wks	N=5	2012

Hackstein1:20	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ CD4+ CD25^hi Foxp3+ CD39+ Treg cells (percentage of CD45+ cells) [%] T_CD4_39 49120	inbred	5	m	7-11wks	N=5	2012

Hackstein1:21	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD3+ gamma-delta T cells (percentage of CD45+ cells) [%] T_gd 49121	inbred	5	m	7-11wks	N=9	2012

Hackstein1:22	Hackstein1	immune cell quantification	(none)	bronchoalveolar lavage CD49+ natural killer (NK) cells (percentage of CD45+ cells) [%] NK 49122	inbred	5	m	7-11wks	N=9	2012

Harrill1:11	Harrill1	organ weights	isoniazid	spleen weight [g] spleen 39511 control isoniazid	inbred	34	f	8-10wks	N=4	2011

Harrill1:13	Harrill1	organ weights	isoniazid	spleen weight as percentage of body weight [%] pct_spleen 39513 control isoniazid	inbred	34	f	8-10wks	N=4	2011

Haston1:3	Haston1	bronchoalveolar lavage assessment	radiation	percentage of macrophages in bronchoalveolar lavage [%] BAL_mac 48803	inbred	26	both	15-36wks	N=6	2012

Haston1:4	Haston1	bronchoalveolar lavage assessment	radiation	percentage of lymphocytes in bronchoalveolar lavage [%] BAL_lym 48804	inbred	26	both	15-36wks	N=6	2012

Haston1:5	Haston1	bronchoalveolar lavage assessment	radiation	percentage of neutrophils in bronchoalveolar lavage [%] BAL_neut 48805	inbred	26	both	15-36wks	N=6	2012

Haston1:6	Haston1	histopathology	radiation	average number of mast cells per mm² of lung tissue [n] mast_cells 48806	inbred	25	both	15-36wks	N=6	2012

Hillebrands1:1	Hillebrands1	histopathology	(none)	number of perivascular immune cell clusters per renal cross-section [n] clusternum 51101	inbred	23	both	90wks	N=7	2014

Hillebrands1:2	Hillebrands1	histopathology	(none)	relative size of perivascular immune cell clusters [%] clustersize 51102	inbred	20	both	90wks	N=7	2014

HMDPpheno5:1	HMDPpheno5	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC 48901	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:7	HMDPpheno5	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYM 48907	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:13	HMDPpheno5	complete blood count	(none)	lymphocyte differential (LYM; percentage of viable WBC) [%] pct_LYM 48913	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:19	HMDPpheno5	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 48919	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:25	HMDPpheno5	complete blood count	(none)	monocyte differential (MONO; percentage of viable WBC) [%] pct_MONO 48925	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:31	HMDPpheno5	complete blood count	(none)	granulocyte count (GRA; units per volume x 10³) [n/µL] GRA 48931	HMDP w/par	79	m	16wks	N=3	2013

HMDPpheno5:37	HMDPpheno5	complete blood count	(none)	granulocyte differential (GRA; percentage of total viable WBC) [%] pct_GRA 48937	HMDP w/par	79	m	16wks	N=3	2013

Jax2:3	Jax2	MHC haplotype tissue typing	(none)	major histocompatibility complex (MHC) H2 haplotype [designation] h2_haplotype 9303 categorical	inbred		both			2000

JaxCC1:9209	JaxCC1	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC 89209	CC	18	both	17-19wks	N=6	2017

JaxCC1:9210	JaxCC1	complete blood count	(none)	basophil differential (percent of total WBC) [%] pct_BASO 89210	CC	18	both	17-19wks	N=6	2017

JaxCC1:9211	JaxCC1	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] pct_EOS 89211	CC	18	both	17-19wks	N=6	2017

JaxCC1:9212	JaxCC1	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] pct_LYM 89212	CC	18	both	17-19wks	N=6	2017

JaxCC1:9213	JaxCC1	complete blood count	(none)	monocyte differential (percent of total WBC) [%] pct_MONO 89213	CC	18	both	17-19wks	N=6	2017

JaxCC1:9214	JaxCC1	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] pct_NEUT 89214	CC	18	both	17-19wks	N=6	2017

JaxCC1:9215	JaxCC1	complete blood count	(none)	large unstained cells (percent of total WBC) [%] pct_LUC 89215	CC	18	both	17-19wks	N=6	2017

JaxKOMP-EAP:423	JaxKOMP-EAP	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC white_blood_cells_wbc 100281	KOMP	1833	both	18wks	N=7	2021

JaxKOMP-EAP:435	JaxKOMP-EAP	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] pct_NEUT neutrophils_neut 100293	KOMP	1833	both	18wks	N=7	2021

JaxKOMP-EAP:436	JaxKOMP-EAP	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] pct_LYM lymphocytes_lym 100294	KOMP	1833	both	18wks	N=7	2021

JaxKOMP-EAP:437	JaxKOMP-EAP	complete blood count	(none)	monocyte differential (percent of total WBC) [%] pct_MONO monocytes_mono 100295	KOMP	1833	both	18wks	N=7	2021

JaxKOMP-EAP:438	JaxKOMP-EAP	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] pct_EOS eosinophils_eos 100296	KOMP	1832	both	18wks	N=7	2021

JaxKOMP-EAP:439	JaxKOMP-EAP	complete blood count	(none)	large unstained cells (percent of total WBC) [%] pct_LUC pct_large_unstained_cells_luc 100297	KOMP	1442	both	18wks	N=7	2021

JaxKOMP-EAP:440	JaxKOMP-EAP	complete blood count	(none)	basophil differential (percent of total WBC) [%] pct_BASO basophils_baso 100298	KOMP	1825	both	18wks	N=7	2021

JaxKOMP-EAP:446	JaxKOMP-EAP	organ weights	(none)	spleen weight [g] spleen_weight 100707	KOMP	132	both	18wks	N=2	2016

JaxKOMP-LAP:311	JaxKOMP-LAP	complete blood count	(none)	white blood cell count (WBC; units per volume x 10³) [n/µL] WBC white_blood_cells_wbc 101281	KOMP	100	both	75-81wks	N=6	2021

JaxKOMP-LAP:323	JaxKOMP-LAP	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] pct_NEUT neutrophils_neut 101293	KOMP	100	both	75-81wks	N=6	2021

JaxKOMP-LAP:324	JaxKOMP-LAP	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] pct_LYM lymphocytes_lym 101294	KOMP	100	both	75-81wks	N=6	2021

JaxKOMP-LAP:325	JaxKOMP-LAP	complete blood count	(none)	monocyte differential (percent of total WBC) [%] pct_MONO monocytes_mono 101295	KOMP	102	both	75-81wks	N=6	2021

JaxKOMP-LAP:326	JaxKOMP-LAP	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] pct_EOS eosinophils_eos 101296	KOMP	101	both	75-81wks	N=6	2021

JaxKOMP-LAP:327	JaxKOMP-LAP	complete blood count	(none)	large unstained cells (percent of total WBC) [%] pct_LUC pct_large_unstained_cells_luc 101297	KOMP	62	both	75-81wks	N=6	2021

JaxKOMP-LAP:328	JaxKOMP-LAP	complete blood count	(none)	basophil differential (percent of total WBC) [%] pct_BASO basophils_baso 101298	KOMP	99	both	75-81wks	N=6	2021

Jaxpheno2:40	Jaxpheno2	organ weights	(none)	spleen weight [g] spleen 22740 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno2:42	Jaxpheno2	organ weights	(none)	spleen weight, as percentage of body weight [%] pct_spleen 22742 age 8wks age 16wks	inbred	11	both		N=8	2006

Jaxpheno4:1	Jaxpheno4	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 22901 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:10	Jaxpheno4	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 22910 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:12	Jaxpheno4	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYMPH 22912 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:14	Jaxpheno4	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 22914 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:16	Jaxpheno4	complete blood count	(none)	eosinophil count (EOS; units per volume x 10³) [n/µL] EOS 22916 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:18	Jaxpheno4	complete blood count	(none)	basophil count (BASO; units per volume x 10³) [n/µL] BASO 22918 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:30	Jaxpheno4	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pct_NEUT 22930 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:32	Jaxpheno4	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pct_LYMPH 22932 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:34	Jaxpheno4	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pct_MONO 22934 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:36	Jaxpheno4	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pct_EOS 22936 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno4:38	Jaxpheno4	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pct_BASO 22938 age 8wks age 16wks	inbred	11	both		N=17	2006

Jaxpheno6:1	Jaxpheno6	immune cell quantification	(none)	splenic CD4 T cells (percentage of total viable cells) [%] pct_CD4 23101 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:3	Jaxpheno6	immune cell quantification	(none)	splenic CD8 T cells (percentage of total viable cells) [%] pct_CD8 23103 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:5	Jaxpheno6	immune cell quantification	(none)	splenic NK T cells (percentage of total viable cells) [%] pct_NKT 23105 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:7	Jaxpheno6	immune cell quantification	(none)	splenic NK cells (percentage of total viable cells) [%] pct_NK 23107 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:9	Jaxpheno6	immune cell quantification	(none)	splenic B cells (percentage of total viable cells) [%] pct_B 23109 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:20	Jaxpheno6	immune cell quantification	(none)	splenic granulocytes (percentage of total viable cells) [%] pct_Granu 23120 8wks 16wks	inbred	11	both		N=9	2006

Jaxpheno6:22	Jaxpheno6	immune cell quantification	(none)	splenic monocytes (percentage of total viable cells) [%] pct_Mono 23122 8wks 16wks	inbred	11	both		N=9	2006

Justice2:4	Justice2	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 13204	inbred	16	both	12-16wks	N=12	2002

Justice2:14	Justice2	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctN 13214	inbred	16	both	12-16wks	N=12	2002

Justice2:15	Justice2	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pctL 13215	inbred	16	both	12-16wks	N=12	2002

Justice2:16	Justice2	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctM 13216	inbred	16	both	12-16wks	N=12	2002

Justice2:17	Justice2	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctE 13217	inbred	16	both	12-16wks	N=12	2002

Justice2:18	Justice2	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctB 13218	inbred	16	both	12-16wks	N=12	2002

Lake1:1	Lake1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 19901	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:3	Lake1	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pct_NEUT 19903	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:4	Lake1	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pct_LYM 19904	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:5	Lake1	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pct_MONO 19905	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:6	Lake1	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pct_EOS 19906	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:7	Lake1	complete blood count	(none)	large unstained cell differential (LUC; percentage of total WBC) [%] pct_LUC 19907	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:8	Lake1	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pct_BASO 19908	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:80	Lake1	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 19980	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:81	Lake1	complete blood count	(none)	lymphocyte count (LYMP; units per volume x 10³) [n/µL] LYM 19981	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:82	Lake1	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 19982	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:83	Lake1	complete blood count	(none)	eosinophil count (EOS; units per volume x 10³) [n/µL] EOS 19983	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:84	Lake1	complete blood count	(none)	large unstained cells count (LUC; units per volume x 10³) [n/µL] LUC 19984	B6.A consomic w/par	23	both	7wks	N=8	2005

Lake1:85	Lake1	complete blood count	(none)	basophil count (BASO; units per volume x 10³) [n/µL] BASO 19985	B6.A consomic w/par	23	both	7wks	N=8	2005

Leiter2:1	Leiter2	health assessment	(none)	age of diabetes onset (dash = no diabetes) [wks] Onset 24001	QTL population		f	14-40wks	N=310	2009

Leiter2:2	Leiter2	health assessment	(none)	1 = diabetes, 0 = no diabetes [score] DB1_0 24002	QTL population		f	14-40wks	N=310	2009

Leiter2:3	Leiter2	histopathology	(none)	combination score of age at type 1 diabetes onset, and insulitis severity / extent (see excel file) [score] Insulities_TimeOnset 24003	QTL population		f	14-40wks	N=310	2009

Leiter2:4	Leiter2	histopathology	(none)	insulitis severity / extent score (0-4, see excel file) [score] Insulitis 24004	QTL population		f	14-40wks	N=310	2009

Leiter2:5	Leiter2	histopathology	(none)	group mice by insulitis score (0-3, see excel file) [score] GroupInsulitis_Diabetes 24005	QTL population		f	14-40wks	N=310	2009

Lesage1:1	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD3- [%] CD3_neg 63501	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:2	Lesage1	immune cell quantification	(none)	percentage of splenic CD3- lymphocytes that are NK cells (CD49+ CD19-) [%] NK_cells_of_CD3_neg 63502	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:3	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are NK cells (CD49+ CD19-) [%] NK_cells_of_tot 63503	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:4	Lesage1	immune cell quantification	(none)	percentage of splenic NK cells that are CD27- CD11b- [%] CD27_neg_CD11b_neg 63504	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:5	Lesage1	immune cell quantification	(none)	percentage of splenic NK cells that are CD27+ CD11b- [%] CD27_pos_CD11b_neg 63505	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:6	Lesage1	immune cell quantification	(none)	percentage of splenic NK cells that are CD27+ CD11b+ [%] CD27_pos_CD11b_pos 63506	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:7	Lesage1	immune cell quantification	(none)	percentage of splenic NK cells that are CD27- CD11b+ [%] CD27_neg_CD11b_pos 63507	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:8	Lesage1	immune cell quantification	(none)	percentage of splenic NK cells that are pre-mNK (B220+ CD11c+) [%] pre_mNK_of_NK 63508	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:9	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are pre-mNK (B220+ CD11c+) [%] pre_mNK_of_tot 63509	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:10	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are NK T cells (TCRb+ CD1d+) [%] NKT_cells 63510	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:11	Lesage1	immune cell quantification	(none)	percentage of splenic NK T cells that are CD4+ CD8- [%] CD4_pos_CD8_neg_of_NKT 63511	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:12	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4+ NK T cells [%] CD4_pos_CD8_neg_NKT_of_tot 63512	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:13	Lesage1	immune cell quantification	(none)	percentage of splenic NK T cells that are CD4- CD8- [%] CD4_neg_CD8_neg_of_NKT 63513	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:14	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4- CD8- NK T cells [%] CD4_neg_CD8_neg_NKT_of_tot 63514	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:15	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are T cells [%] T_cells 63515	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:16	Lesage1	immune cell quantification	(none)	percentage of splenic T cells that are CD4+ CD8- [%] CD4_pos_CD8_neg_of_Tcells 63516	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:17	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4+ T cells [%] CD4_pos_CD8_neg_of_tot 63517	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:18	Lesage1	immune cell quantification	(none)	percentage of splenic T cells that are CD4- CD8+ [%] CD4_neg_CD8_pos_of_Tcells 63518	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:19	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD8+ T cells [%] CD4_neg_CD8_pos_of_tot 63519	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:20	Lesage1	immune cell quantification	(none)	percentage of splenic T cells that are CD4- CD8- [%] CD4_neg_CD8_neg_of_Tcells 63520	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:21	Lesage1	immune cell quantification	(none)	percentage of splenic lymphocytes that are CD4- CD8- T cells [%] CD4_neg_CD8_neg_of_tot 63521	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:22	Lesage1	immune cell quantification	(none)	ratio of splenic CD4+ to CD8+ T cells [ratio] CD4_CD8_ratio 63522	CC w/par	76	both	5-8wks	N=2	2018

Lesage1:23	Lesage1	immune cell quantification	(none)	percentage of splenic leukocytes that are plasmacytoid dendritic cells [%] pDC 63523	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:24	Lesage1	immune cell quantification	(none)	percentage of splenic leukocytes that are conventional dendritic cells [%] cDC 63524	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:25	Lesage1	immune cell quantification	(none)	percentage of splenic conventional dendritic cells that are merocytic [%] mDC_of_cDC 63525	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:26	Lesage1	immune cell quantification	(none)	percentage of splenic leukocytes that are merocytic dendritic cells [%] mDC_of_tot 63526	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:27	Lesage1	immune cell quantification	(none)	percentage of splenic conventional dendritic cells that are cDC1 [%] cDC1_of_cDC 63527	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:28	Lesage1	immune cell quantification	(none)	percentage of splenic leukocytes that are cDC1 conventional dendritic cells [%] cDC1_of_tot 63528	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:29	Lesage1	immune cell quantification	(none)	percentage of splenic conventional dendritic cells that are cDC2 [%] cDC2_of_cDC 63529	CC w/par	74	both	5-8wks	N=2	2018

Lesage1:30	Lesage1	immune cell quantification	(none)	percentage of splenic leukocytes that are cDC2 conventional dendritic cells [%] cDC2_of_tot 63530	CC w/par	74	both	5-8wks	N=2	2018

Lesage2:9	Lesage2	immune cell quantification	(none)	total number of splenic lymphocytes (x 10⁶) [n] spleen_cells_tot 131924	CC w/par	76	both	5-8wks	N=2	2024

Lesage2:10	Lesage2	immune cell quantification	(none)	number of B cells in spleen (x 10⁶) [n] B_cells_tot 131925	CC w/par	76	both	5-8wks	N=2	2024

Lesage2:11	Lesage2	immune cell quantification	(none)	percentage of splenic lymphocytes that are B cells (CD3-CD49b-B220+CD19+) [%] B_cells_pct 131926	CC w/par	76	both	5-8wks	N=2	2024

Mahler1:1	Mahler1	organ weights	(none)	spleen to body weight ratio, first Principal Component [ratio] SplBW 12101	QTL population		both	6wks	N=102	2002

Mahler1:2	Mahler1	histopathology	(none)	cecum assessment, first Principal Component CecumPC1 12102	QTL population		both	6wks	N=102	2002

Mahler1:3	Mahler1	histopathology	(none)	proximal colon assessment, first Principal Component ProxPC1 12103	QTL population		both	6wks	N=102	2002

Mahler1:4	Mahler1	histopathology	(none)	middle colon assessment, first Principal Component MidPC1 12104	QTL population		both	6wks	N=102	2002

Mahler1:5	Mahler1	histopathology	(none)	distal colon assessment, first Principal Component DistPC1 12105	QTL population		both	6wks	N=102	2002

Mahler1:6	Mahler1	histopathology	(none)	ulceration (score 0-4, increasing severity), first Principal Component Ulceration-PC1 12106	QTL population		both	6wks	N=102	2002

Mahler1:7	Mahler1	histopathology	(none)	ulceration (score 0-4, increasing severity), second Principal Component Ulceration-PC2 12107	QTL population		both	6wks	N=102	2002

Mathews1:1	Mathews1	histopathology	(none)	Clinical T1DM accompanied by end-stage insulitis before necropsy (score 0=non-diabetes, 1=diabetes) [score] IDDM 13401	QTL population		f	8-40wks	N=120	2003

Mathews1:2	Mathews1	histopathology	(none)	severity of diabetes (score 0=non-diabetes, 1=diabetes, 2=severe diabetes) [score] IDDM_VS_HI 13402	QTL population		f	8-40wks	N=120	2003

Mathews1:3	Mathews1	histopathology	(none)	Clinical T1DM accompanied by end-stage insulitis diagnosed at necropsy (score 0=non-diabetes, 1=diabetes) [score] IDM 13403	QTL population		f	8-40wks	N=120	2003

Mills1:5	Mills1	apoptosis assessment	(none)	early apoptotic splenocytes [%] early_apoptotic 25205 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mills1:11	Mills1	apoptosis assessment	(none)	late apoptotic splenocytes [%] late_apoptotic 25211 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mills1:17	Mills1	apoptosis assessment	(none)	all apoptotic splenocytes [%] all_apoptotic 25217 6mo 12mo 20mo	inbred	30	both		N=3	2008

Mrug1:3	Mrug1	histopathology	(none)	cholangitis severity (score 0-4, increasing severity) 0 = no/minimal inflammation, 4=severe and extensive cholangiohepatitis [score] Cholangitis 17503	QTL population		both	10d	N=230	2005

Peters1:1	Peters1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 6201	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:11	Peters1	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] NEUT 6211	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:12	Peters1	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] LYM 6212	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:13	Peters1	complete blood count	(none)	monocyte differential (percent of total WBC) [%] MONO 6213	inbred w/CC7	43	both	10wks	N=11	2001

Peters1:14	Peters1	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] EOS 6214	inbred w/CC7	43	both	10wks	N=11	2001

Peters1:15	Peters1	complete blood count	(none)	large unstained cell differential (percent of total WBC) [%] LUC 6215	inbred w/CC7	43	both	10wks	N=12	2001

Peters1:16	Peters1	complete blood count	(none)	basophil differential (percent of total WBC) [%] BASO 6216	inbred w/CC7	43	both	10wks	N=11	2001

Peters2:1	Peters2	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 6501	AXB BXA	28	both	11wks	N=8	2004

Peters2:11	Peters2	complete blood count	(none)	neutrophil differential (percent of total WBC) [%] NEUT 6511	AXB BXA	28	both	11wks	N=8	2004

Peters2:12	Peters2	complete blood count	(none)	lymphocyte differential (percent of total WBC) [%] LYM 6512	AXB BXA	28	both	11wks	N=8	2004

Peters2:13	Peters2	complete blood count	(none)	monocyte differential (percent of total WBC) [%] MONO 6513	AXB BXA	28	both	11wks	N=8	2004

Peters2:14	Peters2	complete blood count	(none)	eosinophil differential (percent of total WBC) [%] EOS 6514	AXB BXA	28	both	11wks	N=8	2004

Peters2:15	Peters2	complete blood count	(none)	large unstained cell differential (percent of total WBC) [%] LUC 6515	AXB BXA	28	both	11wks	N=8	2004

Peters2:16	Peters2	complete blood count	(none)	basophil differential (percent of total WBC) [%] BASO 6516	AXB BXA	28	both	11wks	N=8	2004

Peters4:1	Peters4	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 24301 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:9	Peters4	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 24309 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:13	Peters4	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYMPH 24313 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:17	Peters4	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 24317 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:21	Peters4	complete blood count	(none)	eosinophil count (EOS; units per volume x 10³) [n/µL] EOS 24321 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:25	Peters4	complete blood count	(none)	basophil count (BASO; units per volume x 10³) [n/µL] BASO 24325 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:29	Peters4	complete blood count	(none)	large unstained cells count (LUC; units per volume x 10³) [n/µL] LUC 24329 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:33	Peters4	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctNEUT 24333 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:37	Peters4	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pctLYMPH 24337 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:41	Peters4	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctMONO 24341 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:45	Peters4	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 24345 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:49	Peters4	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctBASO 24349 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:53	Peters4	complete blood count	(none)	large unstained cells differential (LUC; percentage of total WBC) [%] pctLUC 24353 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Petkova1:1	Petkova1	immune cell quantification	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 24201 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:6	Petkova1	immune cell quantification	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] LYM 24206 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:11	Petkova1	immune cell quantification	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] NEUT 24211 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:16	Petkova1	immune cell quantification	(none)	eosinophil differential (EOS; percentage of total WBC) [%] EOS 24216 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:21	Petkova1	immune cell quantification	(none)	monocyte differential (MONO; percentage of total WBC) [%] MONO 24221 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:25	Petkova1	immune cell quantification	(none)	B cells, as percentage of total lymphocytes [%] B_cells 24225 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:29	Petkova1	immune cell quantification	(none)	CD4 T cells, as percentage of total lymphocytes [%] CD4_all 24229 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:33	Petkova1	immune cell quantification	(none)	CD4 T cells, naive, as percentage of total CD4 T cells [%] CD4_naive 24233 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:37	Petkova1	immune cell quantification	(none)	CD4 T cells, central memory, as percentage of total CD4 T cells [%] CD4_mem_central 24237 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:41	Petkova1	immune cell quantification	(none)	CD4 T cells, effector memory, as percentage of total CD4 T cells [%] CD4_mem_effector 24241 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:46	Petkova1	immune cell quantification	(none)	CD4 T cells, effector, as percentage of total CD4 T cells [%] CD4_effector 24246 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:51	Petkova1	immune cell quantification	(none)	CD8 T cells, as percentage of total lymphocytes [%] CD8_all 24251 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:56	Petkova1	immune cell quantification	(none)	CD8 T cells, naive, as percentage of total CD8 T cells [%] CD8_naive 24256 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:61	Petkova1	immune cell quantification	(none)	CD8 T cells, central memory, as percentage of total CD8 T cells [%] CD8_mem_central 24261 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:66	Petkova1	immune cell quantification	(none)	CD8 T cells, effector memory, as percentage of total CD8 T cells [%] CD8_mem_effector 24266 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:71	Petkova1	immune cell quantification	(none)	CD8 T cells, effector, as percentage of total CD8 T cells [%] CD8_effector 24271 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Petkova1:76	Petkova1	immune cell quantification	(none)	natural killer (NK) cells, as percentage of total lymphocytes [%] NK 24276 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Powell1:1	Powell1	in vitro assay	Neisseria musculi	oral cavity bacterial colony count (CFU/swab) post inoculation (x 10³) [n] bacterial_load 62801 wk 1 wk 2 wk 3 wk 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk 11 wk 12	inbred	8	both	8-16wks	N=12	2018

Reed2:56	Reed2	organ weights	(none)	spleen weight [g] spleen_wt 53156	B6.129 and 129.B6 consomic w/par	9	both	26wks	N=17	2015

Reifsnyder2:1	Reifsnyder2	histopathology	(none)	the week of clinical diabetes onset [n] Onset 17601	QTL population		f	12-40wks	N=185	2005

Reifsnyder2:2	Reifsnyder2	histopathology	(none)	insulitis score of diabetes-free mice, (from 0.002=virtually no insulitis, to 1.0=incipient diabetic) Insulitis_Index 17602	QTL population		f	12-40wks	N=185	2005

Reifsnyder2:3	Reifsnyder2	histopathology	(none)	first principal component of age at diabetes onset and severity/extent of insulitis Prin1 17603	QTL population		f	12-40wks	N=185	2005

Reifsnyder2:4	Reifsnyder2	histopathology	(none)	second principal component of age at diabetes onset and severity / extent of insulitis Prin2 17604	QTL population		f	12-40wks	N=185	2005

RIKEN-EAD1:16	RIKEN-EAD1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 37216	inbred RBRC	45	both	8wks	N=11	2008

RIKEN-EAD2:16	RIKEN-EAD2	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 37816	wild-derived RBRC	29	both	8wks	N=12	2008

Rodriguez1:1	Rodriguez1	in vitro assay	(none)	spleen and liver murine cytomegalovirus genome levels (normalized to endogenous b-actin) [ratio] CMV_LEVELS 24101	QTL population		both	8-12wks	N=92	2009

Schoonjans1:222	Schoonjans1	organ weights	high-fat diet	spleen weight [g] spleen_wt 112857 CD HFD	BXD w/par	35	m	29wks	N=5	2021

Schughart1:5	Schughart1	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 39305	inbred	9	both	10-12wks	N=11	2009

Schughart2:6	Schughart2	health assessment	influenza A (H1N1) virus	survival, post-infection [d] survival_days 49606	BXD w/par	56	f	9-18wks	N=6	2012

Schughart2:7	Schughart2	health assessment	influenza A (H1N1) virus	susceptibility to viral infection (0=susceptible; 1=resistant) [designation] susceptibility 49607	BXD w/par	56	f	9-18wks	N=6	2012

Schughart3:11	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 10 FFU group [%] pctbwA 57111 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred w/CC8	8	both	7-13wks	N=9	2013

Schughart3:31	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 2000 FFU group [%] pctbwB 57131 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred w/CC8	8	both	7-13wks	N=9	2013

Schughart3:51	Schughart3	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 200,000 FFU group [%] pctbwC 57151 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14	inbred	2	both	7-13wks	N=12	2013

Schughart3:81	Schughart3	health assessment	influenza A (H3N2) virus	survival, post-infection [d] day_survival 57181 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart3:91	Schughart3	health assessment	influenza A (H3N2) virus	susceptibility to viral infection (0=resistant, 1=susceptible), mortality rate [score] status_day_survival 57191 10 FFU group 2000 FFU group 200000 FFU group	inbred w/CC8	8	both	7-13wks	N=11	2013

Schughart4:11	Schughart4	body weight	(none)	body weight as percent of baseline, control (saline) group [%] pctbw_ctrl 58711 days post-treatment (saline): 1 2 3	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:21	Schughart4	body weight	influenza A (H3N2) virus	body weight as percent of baseline, infected group [%] pctbw_trt 58721 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 30	inbred w/CC8	8	f	8-12wks	N=11	2016

Schughart4:41	Schughart4	complete blood count	influenza A (H3N2) virus	white blood cell count (WBC; per volume x 10³), control group, day 3 [n/µL] WBC_ctrl_d3 58741	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart4:43	Schughart4	complete blood count	influenza A (H3N2) virus	white blood cell count (WBC; per volume x 10³), treated group [n/µL] WBC_trt 58743 days post-infection: 3 5 8 18 30	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:51	Schughart4	complete blood count	influenza A (H3N2) virus	lymphocyte differential (percent of total WBC), control group, day 3 [%] pctLYM_ctrl_d3 58751	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart4:53	Schughart4	complete blood count	influenza A (H3N2) virus	lymphocyte differential (LYM; percentage of total WBC), treated group [%] pctLYM_trt 58753 days post-infection: 3 5 8 18 30	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:61	Schughart4	complete blood count	influenza A (H3N2) virus	monocyte differential (percent of total WBC), control group, day 3 [%] pctMONO_ctrl_d3 58761	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart4:63	Schughart4	complete blood count	influenza A (H3N2) virus	monocyte differential (MONO; percentage of total WBC), treated group [%] pctMONO_trt 58763 days post-infection: 3 5 8 18 30	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:71	Schughart4	complete blood count	influenza A (H3N2) virus	granulocyte differential (percent of total WBC), control group, day 3 [%] pctGRA_ctrl_d3 58771	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart4:73	Schughart4	complete blood count	influenza A (H3N2) virus	granulocyte differential (GRA; percentage of total WBC), treated group [%] pctGRA_trt 58773 days post-infection: 3 5 8 18 30	inbred w/CC8	8	f	8-12wks	N=6	2016

Schughart4:83	Schughart4	in vitro assay	influenza A (H3N2) virus	viral load in lungs (titer, FFU per lung) log10 (x+1) [log(n)] titer_trt 58783 days post-infection: 3 5 8	inbred w/CC8	8	f	8-12wks	N=5	2016

Schughart5:11	Schughart5	body weight	(none)	body weight as percent of baseline [%] pctbw 58811 days post-treatment (saline): 1 2 3	inbred w/CC8	8	f	8-12wks	N=4	2016

Schughart5:21	Schughart5	body weight	influenza A (H3N2) virus	body weight as percent of baseline, 10 FFU group [%] pctbw_trt 58821 days post-infection: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 18 30	inbred w/CC8	8	f	8-12wks	N=9	2016

Schwartz2:1	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), pre-challenge [%] pctEOS0 9801 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:2	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 24h post-challenge [%] pctEOS24 9802 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:3	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 48h post-challenge [%] pctEOS48 9803 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:4	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar eosinophils (percentage of total lavage cells), 72h post-challenge [%] pctEOS72 9804 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:21	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), pre-challenge [%] pctLYM0 9821 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:22	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 24h post-challenge [%] pctLYM24 9822 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:23	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 48h post-challenge [%] pctLYM48 9823 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:24	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar lymphocytes (percentage of total lavage cells), 72h post-challenge [%] pctLYM72 9824 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:41	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), pre-challenge [%] pctNEUT0 9841 pre-test: control OVA-sensitized	inbred	8	m	6-8wks	N=3	2001

Schwartz2:42	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 24h post-challenge [%] pctNEUT24 9842 24h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:43	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 48h post-challenge [%] pctNEUT48 9843 48h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Schwartz2:44	Schwartz2	bronchoalveolar lavage assessment	ovalbumin	alveolar neutrophils (percentage of total lavage cells), 72h post-challenge [%] pctNEUT72 9844 72h post: control OVA-sensitized	inbred	8	m	6-8wks	N=5	2001

Sundberg2:1	Sundberg2	histopathology	(none)	Alopecia areata diagnosis (score 0=no alopecia, 1=alopecia) [score] alopecia_score 13501	QTL population		both	52wks	N=184	2003

Svenson3:1	Svenson3	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 27301	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Svenson3:3	Svenson3	complete blood count	(none)	neutrophil differential (NEUT; percentage of total WBC) [%] pctNEUT 27303	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Svenson3:4	Svenson3	complete blood count	(none)	lymphocyte differential (LYM; percentage of total WBC) [%] pctLYM 27304	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Svenson3:5	Svenson3	complete blood count	(none)	monocyte differential (MONO; percentage of total WBC) [%] pctMONO 27305	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Svenson3:6	Svenson3	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 27306	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Svenson3:7	Svenson3	complete blood count	(none)	basophil differential (BASO; percentage of total WBC) [%] pctBASO 27307	B6.PWD consomic w/par	27	both	7wks	N=8	2006

Svenson3:8	Svenson3	complete blood count	(none)	large unstained cell differential (LUC; percentage of total WBC) [%] pctLUC 27308	B6.PWD consomic w/par	28	both	7wks	N=8	2006

Williams1:1	Williams1	immune cell quantification	(none)	CD4 Treg cells (CD25+ CD44^int; as percentage of lymphocytes) [%] Treg 42901	inbred	5	f	8wks	N=3	2012

Williams1:2	Williams1	immune cell quantification	(none)	CD4 Treg cells (CD25+ CD44^int; as percentage of CD4 T cells) [%] Treg_adj 42902	inbred	5	f	8wks	N=3	2012

Williams1:3	Williams1	immune cell quantification	(none)	memory-effector CD4 T cells (CD25^- CD44^hi; as percentage of lymphocytes) [%] memoryT 42903	inbred	5	f	8wks	N=3	2012

Williams1:4	Williams1	immune cell quantification	(none)	memory-effector CD4 T cells (CD25^- CD44^hi; as percentage of CD4 T cells) [%] memoryT_adj 42904	inbred	5	f	8wks	N=3	2012

Williams1:5	Williams1	immune cell quantification	(none)	naive CD4 T cells (CD25^- CD44^lo; as percentage of lymphocytes) [%] naiveT 42905	inbred	5	f	8wks	N=3	2012

Williams1:6	Williams1	immune cell quantification	(none)	naive CD4 T cells (CD25^- CD44^lo; as percentage of CD4 T cells) [%] naiveT_adj 42906	inbred	5	f	8wks	N=3	2012

Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:7	Wiltshire4	immune cell quantification	BEZ235	T cells, percent viability [%] Tcells_BEZ 52407 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:13	Wiltshire4	immune cell quantification	BEZ235	monocytes, percent viability [%] monocytes_BEZ 52413 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:21	Wiltshire4	immune cell quantification	doxorubicin	B cells, percent viability [%] Bcells_Dox 52421 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:27	Wiltshire4	immune cell quantification	doxorubicin	T cells, percent viability [%] Tcells_Dox 52427 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:33	Wiltshire4	immune cell quantification	doxorubicin	monocytes, percent viability [%] monocytes_Dox 52433 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:41	Wiltshire4	immune cell quantification	idarubicin	B cells, percent viability [%] Bcells_Ida 52441 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:47	Wiltshire4	immune cell quantification	idarubicin	T cells, percent viability [%] Tcells_Ida 52447 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:53	Wiltshire4	immune cell quantification	idarubicin	monocytes, percent viability [%] monocytes_Ida 52453 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	35	m	10wks	N=4	2015

Wiltshire4:61	Wiltshire4	immune cell quantification	selumetinib	B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:67	Wiltshire4	immune cell quantification	selumetinib	T cells, percent viability [%] Tcells_Sel 52467 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:73	Wiltshire4	immune cell quantification	selumetinib	monocytes, percent viability [%] monocytes_Sel 52473 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

All boxes To see more rows use the paging control at top.

Filter Table Results